Nitin Trivedi, MD
Endocrinology, Diabetes & Metabolism · Worcester, MANPI 1770543977
Payments from drug & device makers
Across 626 payments — averaging $642.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$244K
- Novo Nordisk$45K
- Boehringer Ingelheim$30K
- AstraZeneca$30K
- Sanofi-aventis U.S. LLC$22K
- Johnson & Johnson$11K
- plus $21K from 26 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 331 | $243,529 |
| Novo Nordisk | 72 | $44,509 |
| Boehringer Ingelheim | 48 | $30,225 |
| AstraZeneca(2 entities) | 46 | $30,223 |
| Sanofi-aventis U.S. LLC | 33 | $21,805 |
| Johnson & Johnson | 22 | $11,451 |
| Dexcom, Inc. | 14 | $11,181 |
| Corcept Therapeutics | 10 | $3,783 |
| Zealand Pharma US, Inc. | 2 | $1,600 |
| Medtronic(2 entities) | 8 | $1,416 |
| Eli Lilly | 1 | $1,050 |
| Abbott | 6 | $375 |
| Amgen | 4 | $265 |
| Kyowa Kirin, Inc. | 2 | $151 |
| Ascensia Diabetes Care US Inc. | 1 | $120 |
| Cequr Corporation | 1 | $113 |
| Bigfoot Biomedical Inc | 1 | $111 |
| Ascendis Pharma Endocrinology Inc | 2 | $88 |
| Recordati_rare_diseases_inc. | 3 | $77 |
| Xeris Pharmaceuticals, Inc. | 3 | $66 |
| Tandem Diabetes Care, Inc. | 2 | $63 |
| Novartis | 3 | $63 |
| Bayer | 2 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $33 |
| Radius Health, Inc. | 1 | $28 |
| Madrigal Pharmaceuticals | 1 | $26 |
| Sequel Med Tech, LLC | 1 | $21 |
| Mannkind Corporation | 1 | $21 |
| IBSA Pharma Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $20 |
| Insulet Corporation | 1 | $18 |
| AbbVie | 1 | $16 |
How this compares
$402,513 in reported general payments places this provider in the 90th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
See all endocrinology, diabetes & metabolism providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Worcester
- Nina RosanoWorcester$470K
- David NathanBoston$9M
- Vanita ArodaBoston$4.2M
- George KingBoston$3.7M
- Karen MillerBoston$2.9M
- Steven GrinspoonBoston$2.7M
- Jason GagliaBoston$2.5M
- Tamer YacoubFall River$1.4M
- Elaine YuBoston$1.3M
- Osama HamdyBoston$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.